Phio Pharmaceuticals CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Phio Pharmaceuticals Corp. reports increased cash reserves and progress in its PH-762 clinical trial, bolstered by recent financing activities, while deferring its PH-894 program.
NASDAQ
Phio Pharmaceuticals Corp. reported a net loss of $2.17 million for Q2 2025, while advancing its lead cancer therapeutic PH-762 in clinical trials and securing significant capital.
NASDAQ
Phio Pharmaceuticals reports its Q1 2025 financial results and provides an update on its ongoing clinical trial for PH-762.
NASDAQ
Phio Pharmaceuticals reported its Q3 2024 financial results, highlighting progress in its PH-762 clinical trial and the impact of cost rationalization efforts.
NASDAQ
10-Q: Phio Pharmaceuticals Reports Q2 2024 Results, Cites Cost Rationalization and Clinical Trial Progress
Phio Pharmaceuticals reported its Q2 2024 financial results, highlighting cost rationalization efforts and progress in its PH-762 clinical trial.
NASDAQ
Phio Pharmaceuticals reported a net loss of $2.154 million for the first quarter of 2024, as it continues to advance its clinical programs and streamline operations.